Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.40 |
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.34 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL934011 | 0.98 | ALDH1A1 (0.42) | ALDH1A1TDP1KDM4EMAPTTHRB | |
| SCHEMBL19359995 | 0.98 | ALDH1A1 (0.42) | ALDH1A1TDP1KDM4EMAPTTHRB | |
| SCHEMBL29987645 | 0.98 | ALDH1A1 (0.42) | ALDH1A1TDP1KDM4EMAPTTHRB | |
| SCHEMBL12580526 | 0.98 | ALDH1A1 (0.42) | ALDH1A1TDP1KDM4EMAPTTHRB | |
| SCHEMBL19359998 | 0.86 | MME (0.41) | ALDH1A1TDP1KDM4EMAPTTHRB | |
| N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL10763594 | 0.83 | CA2 (0.44) | TDP1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL30595606 | 0.82 | KDM4E (0.32) | ALDH1A1TDP1KDM4EMAPTTHRB | |
| SCHEMBL29891830 | 0.81 | TSHR (0.45) | ALDH1A1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL13474987 | 0.80 | ALDH1A1 (0.43) | ALDH1A1TDP1 | |
| N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL167682 | 0.80 | CA2 (0.45) | TDP1KDM4EMAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485088-B2 | Rapidly-orodispersible tablets having an interior cavity | Aprecia Pharmaceuticals LLC (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250281407-A1 | LIPID DEPOT FORMULATIONS | CAMURUS AB (SE) | 2025-09-11 | — | — | US | disclosed |
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | Triastek, Inc. (CN) | 2025-06-10 | — | — | US | disclosed |
| EP-4512394-A2 | DOSAGE FORMS AND USE THEREOF | Triastek, Inc. (CN) | 2025-02-26 | — | — | EP | disclosed |
| US-20240408023-A1 | DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES | Triastek, Inc. (CN) | 2024-12-12 | — | — | US | disclosed |
| EP-4171518-B1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240342094-A1 | COMPARTMENTED PHARMACEUTICAL DOSAGE FORMS | Triastek, Inc. (CN) | 2024-10-17 | — | — | US | disclosed |
| EP-3302442-B1 | DOSAGE FORMS AND USE THEREOF | TRIASTEK INC (CN) | 2024-10-16 | — | — | EP | disclosed |
| US-12102721-B2 | Dosage forms of controlled release at specific gastrointestinal sites | Triastek, Inc. (CN) | 2024-10-01 | — | — | US | disclosed |
| CN-118695872-A | Compositions for oral delivery of biologic therapeutic agents | 英特拉克医药有限公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20180116911-A1 | CONTROLLED RELEASE DOSAGE FORM | Triastek, Inc. (CN) | 2018-05-03 | — | — | US | disclosed |
| EP-3302442-A1 | DOSAGE FORMS AND USE THEREOF | Triastek, Inc. (CN) | 2018-04-11 | — | — | EP | disclosed |
| WO-2017193099-A1 | CONTROLLED RELEASE DOSAGE FORM | LI XIAOLING (US) | 2017-11-09 | — | — | WO | disclosed |
| WO-2016192680-A1 | DOSAGE FORMS AND USE THEREOF | Triastek, Inc. (CN) | 2016-12-08 | — | — | WO | disclosed |
| US-20160354315-A1 | DOSAGE FORMS AND USE THEREOF | Triastek, Inc. (CN) | 2016-12-08 | — | — | US | disclosed |
| US-20160030565-A1 | USE OF AMINOLEVULINIC ACID AND DERIVATIVES THEREOF | PHOTOCURE ASA (NO) | 2016-02-04 | — | — | US | disclosed |
| US-20150150972-A1 | USE OF AMINOLEVULINIC ACID AND DERIVATIVES THEREOF | PHOTOCURE ASA (NO) | 2015-06-04 | — | — | US | disclosed |
| US-8920782-B2 | Topical bioadhesive formulations | CAMURUS AB (SE) | 2014-12-30 | — | — | US | disclosed |
| WO-2014027006-A1 | BIOADHESIVE FORMULATIONS FOR USE IN DRUG DELIVERY | EDKO PAZARLAMA TANITIM TICARET LIMITED SIRKETI (TR) | 2014-02-20 | — | — | WO | disclosed |
| US-20090155193-A1 | Topical Bioadhesive Formulations | CAMURUS AB (SE) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281407-A1 | LIPID DEPOT FORMULATIONS | LIPA, DAGLA, PNLIP | PTGS2 368/4885ACE 2961/4885ALDH1A1 1546/4885 |
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | CYP2D6, CYP3A5, CYP3A7 | PTGS2 2407/4885ACE 254/4885ALDH1A1 447/4885 |
| US-20090155193-A1 | Topical Bioadhesive Formulations | TTPA, LIPA, DAGLA | PTGS2 185/4885ACE 1965/4885ALDH1A1 382/4885 |
| US-20160354315-A1 | DOSAGE FORMS AND USE THEREOF | CYP2D6, CYP3A7, CYP3A5 | PTGS2 1614/4885ACE 512/4885ALDH1A1 767/4885 |
| US-20240342094-A1 | COMPARTMENTED PHARMACEUTICAL DOSAGE FORMS | CYP2D6, CYP3A5, CYP2F1 | PTGS2 1583/4885ACE 911/4885ALDH1A1 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.